Close Menu

NEW YORK – Clinical labs and test vendors are anticipating increased demand for SARS-CoV-2 serology testing as vaccine rollouts continue.

Among the uses they cite for serology tests are for determining whether individuals have previously been infected and can, in certain cases, be deprioritized for vaccination and assessing whether vaccines have generated a sufficient immune response to protect against the virus, particularly in immunocompromised populations.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.